sorbaMOF DB Broadens AI Platform Boundaries; Clinical Data and Licensing Deals Remain Core to Re-rating

Overview

The report focuses on Insilico Medicine's joint launch of sorbaMOF DB with Saudi Aramco. The database combines approximately 240,000 metal-organic framework structures with an explainable AI framework, aiming to improve carbon dioxide capture predictions in direct air capture technology. J.P. Morgan believes this development demonstrates that the company's AI capabilities can expand from pharmaceuticals to materials science, energy, and industrial fields, helping diversify clinical risk, but in the short term it is not an event sufficient to independently drive valuation changes.

Core views

The company's core investment thesis remains participation in China's AI drug discovery theme through its end-to-end Pharma.AI platform. Compared with more service-oriented peers, the company has deeper vertical integration capabilities and owns high-value proprietary pipelines, with rentosertib already entering Phase 3 development. A repeatable out-licensing model can monetize the platform through upfront payments, milestone payments, and potential royalties while supporting pipeline expansion. sorbaMOF DB further validates the platform's interdisciplinary applicability and may reduce dependence on a small number of clinical assets; however, future re-rating still depends on key clinical readouts, the speed and value of out-licensing transactions, and commercialization progress of new platform businesses.

Analysis framework

The report first assesses the technical scale, application scenarios, and partner quality of sorbaMOF DB, then analyzes the impact of extending the AI platform from pharmaceuticals to materials science and energy on risk structure and business model. For valuation, it uses a sum-of-the-parts approach, assigning AI-enabled EV/S multiples to drug discovery and software solutions and other businesses respectively, and checks reasonableness against the valuation range of global AI drug discovery peers. Finally, it evaluates upside catalysts and downside risks through clinical, licensing, execution, and geopolitical factors.

Methodology notes

• Valuation methodSum-of-the-parts (SOTP)

  Value the drug discovery business and software solutions and other businesses separately, then aggregate them to derive the company's target value.

  The December 2027 target price of HK$71 is based on SOTP, applying AI-enabled EV/S valuations to the two businesses respectively.

• Relative valuationAI-enabled EV/S and P/S peer comparison

  Use revenue multiples to measure the platform and pipeline value of AI drug discovery companies and compare them with global peers.

  The target price corresponds to approximately 19x expected 2027 P/S, at the lower end of the approximately 5x to 173x range for global AI drug discovery peers and below the median of approximately 60x.

• Event and risk analysisCatalyst pathway analysis

  Assess potential re-rating paths according to the timing of clinical readouts, out-licensing, and platform commercialization.

  Near-term focus is on ISM6331 Phase 1 data and new licensing transactions; medium-term focus is on garutadustat Phase 2 data; long-term focus is on rentosertib Phase 3 results.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Insilico-H (3696.HK)

  Core covered stock in the report, rated Overweight

  Strengths

  Has an end-to-end Pharma.AI platform covering target discovery, molecular design, and clinical trial prediction; holds a pipeline of 30 assets; rentosertib has entered Phase 3; cumulative collaboration contract value exceeds US$7.5bn; the platform is expanding into materials science, energy, agriculture, nutrition, veterinary medicine, and other fields.

  Weaknesses

  Compared with service-oriented peers, the company is more dependent on the success of its proprietary pipeline, with higher clinical and execution risks; the new materials science platform is currently still mainly a strategic validation, with limited near-term valuation contribution.

  Comparison

  Like XtalPi, it benefits from the AI drug R&D trend and milestone-driven model, but Insilico Medicine has a higher degree of vertical integration and owns high-value proprietary pipelines represented by rentosertib.

  Risks

  Unfavorable clinical trial results, slow out-licensing progress or transaction value below expectations, weakening sentiment toward the AI theme, geopolitical risks such as China-U.S. relations, and sales or profit below expectations.

Key data

• Current share priceHK$48.00As of August 11, 2026
• Target priceHK$71.00Target date is December 2027, implying approximately 47.9% upside
• sorbaMOF DB scaleApproximately 240,000 MOF structuresCombined with explainable AI to improve carbon dioxide capture predictions
• R&D pipeline30 assetsSupported by the end-to-end Pharma.AI platform
• Cumulative collaboration contract valueOver US$7.5bnSince 2021, including collaboration with Eli Lilly
• Target price implied valuationApproximately 19x expected 2027 P/SGlobal AI drug discovery peers are approximately 5x to 173x, with a median of approximately 60x
• Near-term clinical catalystISM6331 Phase 1 dataExpected to be released in 2H26
• Medium-term clinical catalystgarutadustat Phase 2 ulcerative colitis dataExpected to be released in 1H27
• Long-term clinical catalystrentosertib Phase 3 resultsExpected to be released in 2029

Impact & implications

sorbaMOF DB provides validation for Insilico Medicine's AI platform in applications beyond pharmaceuticals and strengthens commercial credibility through Saudi Aramco, a major energy company. If the company can translate AI infrastructure licensing and multi-party research collaborations into recurring revenue, its profit sources are expected to become more diversified and reduce the impact of clinical failure of proprietary drugs on overall value. However, the database release is currently more of a strategic validation, and no commercial contribution sufficient to independently change valuation has been disclosed; therefore, share price upside still requires clinical success and the realization of high-value licensing transactions.

Risks

• Unfavorable clinical trial results for key drugs, especially failure of proprietary pipelines, could significantly affect valuation.
• Out-licensing transactions progress slowly, or contract value, upfront payments, and milestone payments fall below expectations.
• Market investment sentiment toward AI and AI drug discovery themes weakens.
• Geopolitical factors such as tensions in China-U.S. relations affect collaboration, financing, or commercialization.
• After the platform expands into materials science and energy, commercialization speed and revenue contribution may be below expectations.
• The company's sales or profitability performance is weaker than expected.

What to watch

• ISM6331 Phase 1 clinical data in 2H26.
• garutadustat Phase 2 clinical data for ulcerative colitis in 1H27.
• Phase 3 results for rentosertib expected to be announced in 2029.
• The number, upfront payments, and cumulative contract value of new collaborations with large multinational companies and out-licensing transactions.
• Progress of sorbaMOF DB expanding beyond carbon dioxide capture into hydrogen, methane, pollutants, and other porous material systems.
• Commercial revenue contribution from non-pharmaceutical scenarios such as materials science, energy, agriculture, nutrition, and veterinary medicine.